spironolactone has been researched along with Injury, Ischemia-Reperfusion in 13 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results show that MR antagonism administered, either immediately or 3 h after I/R, effectively prevented ischemic acute renal injury, indicating that spironolactone is a promising agent for preventing acute kidney injury once an ischemic insult has occurred." | 7.78 | Recovery from ischemic acute kidney injury by spironolactone administration. ( Barrera-Chimal, J; Bobadilla, NA; Cruz, C; Gamba, G; Garzón-Muvdi, J; Pérez-Villalva, R; Rodríguez-Romo, R; Sánchez-Pozos, K, 2012) |
| "Spironolactone is an antagonist of aldosterone that has shown benefits over IR injury in several tissues, but its effects in hepatic IR are unknown." | 5.43 | Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats. ( Chavira, HZ; de la Garza, FJ; Espinosa, LE; Galván, GA; Garza, NE; González, LT; Lemarroy, CR; Pérez, JC; Pérez, PC; Quintana, MM; Ramírez, AC; Rodríguez, EP, 2016) |
| "Spironolactone pretreatment markedly reduced intestinal I/R-induced lung injury as indicated by histology and MDA and MPO levels." | 5.43 | Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. ( Aktunc, E; Barut, F; Ozacmak, VH; Sayan-Ozacmak, H; Turan, I, 2016) |
| "Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury." | 5.38 | Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. ( Fujita, T; Hirooka, K; Itano, T; Lei, B; Liu, Y; Nakamura, T; Nishiyama, A; Shiraga, F; Zhang, J, 2012) |
| "The chronic nandrolone treatment impairs the exercise-induced cardioprotection against ischaemia/reperfusion injury by activating the cardiac renin-angiotensin-aldosterone system and downregulating KATP channel expression." | 3.80 | AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion. ( Campos de Carvalho, AC; Ferraz, EB; Marques-Neto, SR; Nascimento, JH; Njaine, B; Rodrigues, DC; Rondinelli, E, 2014) |
| "Our results show that MR antagonism administered, either immediately or 3 h after I/R, effectively prevented ischemic acute renal injury, indicating that spironolactone is a promising agent for preventing acute kidney injury once an ischemic insult has occurred." | 3.78 | Recovery from ischemic acute kidney injury by spironolactone administration. ( Barrera-Chimal, J; Bobadilla, NA; Cruz, C; Gamba, G; Garzón-Muvdi, J; Pérez-Villalva, R; Rodríguez-Romo, R; Sánchez-Pozos, K, 2012) |
| "Treatment with losartan or spironolactone alone significantly reduced various CKD-associated features." | 1.56 | Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. ( Aggarwal, D; Singh, G, 2020) |
| "Spironolactone is an antagonist of aldosterone that has shown benefits over IR injury in several tissues, but its effects in hepatic IR are unknown." | 1.43 | Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats. ( Chavira, HZ; de la Garza, FJ; Espinosa, LE; Galván, GA; Garza, NE; González, LT; Lemarroy, CR; Pérez, JC; Pérez, PC; Quintana, MM; Ramírez, AC; Rodríguez, EP, 2016) |
| "Spironolactone pretreatment markedly reduced intestinal I/R-induced lung injury as indicated by histology and MDA and MPO levels." | 1.43 | Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. ( Aktunc, E; Barut, F; Ozacmak, VH; Sayan-Ozacmak, H; Turan, I, 2016) |
| "Spironolactone treatment immediately or 1." | 1.42 | Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration. ( Barrera-Chimal, J; Bobadilla, NA; Durand, M; Jaisser, F; Ortega, JA; Pérez-Villalva, R; Rodríguez-Romo, R; Sánchez, A, 2015) |
| "Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury." | 1.38 | Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. ( Fujita, T; Hirooka, K; Itano, T; Lei, B; Liu, Y; Nakamura, T; Nishiyama, A; Shiraga, F; Zhang, J, 2012) |
| "Spironolactone treatment prevents renal damage induced by ischemia-reperfusion (I/R), suggesting that renoprotection conferred by spironolactone is mediated by mineralocorticoid receptor (MR) blockade." | 1.35 | Adrenalectomy prevents renal ischemia-reperfusion injury. ( Bobadilla, NA; Cruz, C; Gamba, G; Ramírez, V; Trujillo, J; Uribe, N; Valdes, R, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, D | 1 |
| Singh, G | 1 |
| Marques-Neto, SR | 1 |
| Ferraz, EB | 1 |
| Rodrigues, DC | 1 |
| Njaine, B | 1 |
| Rondinelli, E | 1 |
| Campos de Carvalho, AC | 1 |
| Nascimento, JH | 1 |
| Ozacmak, HS | 1 |
| Ozacmak, VH | 2 |
| Barut, F | 2 |
| Araslı, M | 1 |
| Ucan, BH | 1 |
| Ashton, AW | 1 |
| Le, TY | 1 |
| Gomez-Sanchez, CE | 1 |
| Morel-Kopp, MC | 1 |
| McWhinney, B | 1 |
| Hudson, A | 1 |
| Mihailidou, AS | 1 |
| Barrera-Chimal, J | 3 |
| Pérez-Villalva, R | 3 |
| Ortega, JA | 1 |
| Sánchez, A | 1 |
| Rodríguez-Romo, R | 2 |
| Durand, M | 1 |
| Jaisser, F | 1 |
| Bobadilla, NA | 5 |
| Pérez, JC | 1 |
| Ramírez, AC | 1 |
| González, LT | 1 |
| Espinosa, LE | 1 |
| Quintana, MM | 1 |
| Galván, GA | 1 |
| Chavira, HZ | 1 |
| de la Garza, FJ | 1 |
| Lemarroy, CR | 1 |
| Garza, NE | 1 |
| Rodríguez, EP | 1 |
| Pérez, PC | 1 |
| Turan, I | 1 |
| Sayan-Ozacmak, H | 1 |
| Aktunc, E | 1 |
| van den Berg, TN | 1 |
| van Swieten, HA | 1 |
| Vos, JC | 1 |
| Verweij, V | 1 |
| Wouterse, AC | 1 |
| Deinum, J | 1 |
| Morshuis, WJ | 1 |
| Rongen, GA | 1 |
| Riksen, NP | 1 |
| Ramírez, V | 2 |
| Trujillo, J | 1 |
| Valdes, R | 1 |
| Uribe, N | 2 |
| Cruz, C | 3 |
| Gamba, G | 4 |
| Cortés-González, C | 1 |
| Ojeda-Cervantes, M | 1 |
| Morales-Buenrostro, LE | 1 |
| Liu, Y | 1 |
| Hirooka, K | 1 |
| Nishiyama, A | 1 |
| Lei, B | 1 |
| Nakamura, T | 1 |
| Itano, T | 1 |
| Fujita, T | 1 |
| Zhang, J | 1 |
| Shiraga, F | 1 |
| Sánchez-Pozos, K | 1 |
| Garzón-Muvdi, J | 1 |
| Mejía-Vilet, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Non Randomised Controlled Trial of Short Term Spironolactone Use for Prevention of Acute Kidney Injury After Cardiac Surgery[NCT02417896] | 150 participants (Anticipated) | Interventional | 2013-04-30 | Recruiting | |||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for spironolactone and Injury, Ischemia-Reperfusion
| Article | Year |
|---|---|
Eplerenone does not limit ischemia-reperfusion injury in human myocardial tissue.
Topics: Aged; Cardiovascular Diseases; Elective Surgical Procedures; Eplerenone; Female; Heart; Heart Atria; | 2016 |
12 other studies available for spironolactone and Injury, Ischemia-Reperfusion
| Article | Year |
|---|---|
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats.
Topics: Animals; Catalase; Cytokines; Glutathione; Kidney; Kidney Diseases; Losartan; Male; Rats, Wistar; Re | 2020 |
AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Heart; KATP Channels; Losartan; Male | 2014 |
Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor κB, and inducible nitric oxide synthase.
Topics: Animals; Glutathione; Inflammation; Male; Mineralocorticoid Receptor Antagonists; Neutrophil Infiltr | 2014 |
Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury.
Topics: Aldosterone; Amines; Animals; Calmodulin-Binding Proteins; Male; Membrane Proteins; Mineralocorticoi | 2015 |
Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration.
Topics: Animals; Ischemia; Kidney; Male; Proteinuria; Rats; Rats, Wistar; Reperfusion Injury; Spironolactone | 2015 |
Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats.
Topics: Animals; Cytokines; Liver; Male; Oxidative Stress; Rats, Wistar; Reperfusion Injury; Spironolactone; | 2016 |
Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats.
Topics: Acute Lung Injury; Animals; Intestinal Diseases; Male; Rats; Rats, Wistar; Reperfusion Injury; Spiro | 2016 |
Adrenalectomy prevents renal ischemia-reperfusion injury.
Topics: Adrenalectomy; Aldosterone; Animals; Kidney; Kidney Diseases; Male; Nitric Oxide; Nitric Oxide Synth | 2009 |
Hsp72 is an early and sensitive biomarker to detect acute kidney injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Biomarkers; Creatine; Hepatitis A Virus Cellular | 2011 |
Hsp72 is an early and sensitive biomarker to detect acute kidney injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Biomarkers; Creatine; Hepatitis A Virus Cellular | 2011 |
Hsp72 is an early and sensitive biomarker to detect acute kidney injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Biomarkers; Creatine; Hepatitis A Virus Cellular | 2011 |
Hsp72 is an early and sensitive biomarker to detect acute kidney injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Biomarkers; Creatine; Hepatitis A Virus Cellular | 2011 |
Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; C | 2012 |
Recovery from ischemic acute kidney injury by spironolactone administration.
Topics: Acute Kidney Injury; Aldosterone; Animals; Drug Administration Schedule; HSP72 Heat-Shock Proteins; | 2012 |
Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.
Topics: Aldosterone; Animals; Blotting, Western; Catalase; Glutathione Peroxidase; Immunohistochemistry; In | 2007 |